Skip to main content

Advertisement

SpringerLink
Log in

Selection of Warfarin or One of the New Oral Antithrombotic Agents for Long-Term Prevention of Stroke among Persons with Atrial Fibrillation

  • Cerebrovascular Disorders (HP Adams, Section Editor)
  • Published:
Current Treatment Options in Neurology Aims and scope Submit manuscript

Opinion statement

Atrial fibrillation (AF) is the most common sustained cardiac rhythm disorder, which can potentially increases the risk of stroke by five-fold, thus, resulting in high public healthcare burden. Stroke prevention is vital in the management of AF patients. Vitamin K antagonists (VKA, eg, warfarin) have been the mainstay treatment to prevent ischemic stroke and systemic thromboembolism in AF patients for several decades. Despite the efficacy of warfarin, its limitations have recently driven the advent of some new antithrombotic agents, the non-VKA oral anticoagulant (NOACs, including dabigatran, rivaroxaban, apixaban, and edoxaban). The NOACs have changed the landscape for thromboembolic prophylaxis among patients with nonvalvular AF. Although three NOACs thus far (dabigatran, rivaroxaban, and apixaban) have been approved in Europe and the United States, for stroke prevention in patients with nonvalvular AF on the basis of several Phase III clinical trials, warfarin still remain important in preventing stroke for patients. This is especially true for those with optimal control of international normalized ratio with high (>70 %) time in therapeutic range, valvular AF or associated prosthetic valve. These NOACs are attractive alternatives for stroke prevention in patients with nonvalvular AF who are unable or unwilling to receive warfarin. However, several issues should be taken into consideration on safe and effective use of these NOACs in day-to-day clinical practice, for example, pharmacological properties, drug interactions, monitoring and compliance, and treatment of frail elderly patients or patients with renal impairment, etc. The decision about whether to initiate oral anticoagulation either with warfarin or NOACs should be patient-centered and after consideration of both stroke and bleeding risks. It is important for clinical practitioner to offer patients with AF an individualized decision about drug choice, making decision after adequate patient education plus discussion about the risks and benefits of these agents, thus fitting the drug to the patient profile.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Cowan C, Healicon R, Robson I, et al. The use of anticoagulants in the management of atrial fibrillation among general practices in England. Heart. 2013;99:1166–72.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  2. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285:2370–5.

    Article  CAS  PubMed  Google Scholar 

  3. Hobbs FD, Fitzmaurice DA, Mant J, et al. A randomised controlled trial and cost-effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in people aged 65 and over. The SAFE study. Health Technol Assess (Winchester, England). 2005;9:iii‒iv, ix‒x, 1‒74.

  4. Lowres N, Neubeck L, Salkeld G, et al. Feasibility and cost-effectiveness of stroke prevention through community screening for atrial fibrillation using iPhone ECG in pharmacies. The SEARCH-AF study. Thromb Haemost. 2014;111:1167–76. This paper demonstrates that screening for unknown AF using iPhone electrocardiogram is both feasible and cost-effective.

    Article  CAS  PubMed  Google Scholar 

  5. Lowres N, Neubeck L, Redfern J, Freedman SB. Screening to identify unknown atrial fibrillation. A systematic review. Thromb Haemost. 2013;110:213–22.

    Article  CAS  PubMed  Google Scholar 

  6. Wolf PA, Dawber TR, Thomas Jr HE, Kannel WB. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study. Neurology. 1978;28:973–7.

    Article  CAS  PubMed  Google Scholar 

  7. Steger C, Pratter A, Martinek-Bregel M, et al. Stroke patients with atrial fibrillation have a worse prognosis than patients without: data from the Austrian Stroke registry. Eur Heart J. 2004;25:1734–40.

    Article  PubMed  Google Scholar 

  8. Apenteng PN, Murray ET, Hobbs FD, Kakkar AK, Fitzmaurice DA. 33Patterns of antithrombotic therapy in relation to type of atrial fibrillation: insights from the UK cohort of the global GARFIELD registry. Europace. 2014;16 Suppl 3:iii14.

    Article  Google Scholar 

  9. Husted S, de Caterina R, Andreotti F, et al. Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel. Thromb Haemost. 2014;111:781–2.

    Article  CAS  PubMed  Google Scholar 

  10. Coppens M, Eikelboom JW, Hart RG, et al. The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy. Eur Heart J. 2013;34:170–6. This study indicates the CHA2DS2-VASc score can ideally identify AF patients with CHADS2 score of 1 who are unlikely to benefit from antithrombotic treatment.

    Article  CAS  PubMed  Google Scholar 

  11. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137:263–72.

    Article  PubMed  Google Scholar 

  12. Olesen JB, Torp-Pedersen C, Hansen ML, Lip GY. The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: a nationwide cohort study. Thromb Haemost. 2012;107:1172–9.

    Article  CAS  PubMed  Google Scholar 

  13. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138:1093–100.

    Article  PubMed  Google Scholar 

  14. Roldan V, Marin F, Manzano-Fernandez S, et al. The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation. J Am Coll Cardiol. 2013;62:2199–204. This study suggests that the HAS-BLED score should be used for assessing major bleeding in anticoagulated patients with AF.

    Article  PubMed  Google Scholar 

  15. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857–67.

    Article  PubMed  Google Scholar 

  16. De Caterina R, Husted S, Wallentin L, et al. General mechanisms of coagulation and targets of anticoagulants (Section I). Position Paper of the ESC Working Group on Thrombosis–Task Force on Anticoagulants in Heart Disease. Thromb Haemost. 2013;109:569–79.

    Article  PubMed  Google Scholar 

  17. Chan NC, Paikin JS, Hirsh J, Lauw MN, Eikelboom JW, Ginsberg JS. New oral anticoagulants for stroke prevention in atrial fibrillation: impact of study design, double counting and unexpected findings on interpretation of study results and conclusions. Thromb Haemost. 2014;111:798–807.

    Article  CAS  PubMed  Google Scholar 

  18. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–51.

    Article  CAS  PubMed  Google Scholar 

  19. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–92.

    Article  CAS  PubMed  Google Scholar 

  20. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–91.

    Article  CAS  PubMed  Google Scholar 

  21. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093–104.

    Article  CAS  PubMed  Google Scholar 

  22. Capodanno D, Capranzano P, Giacchi G, Calvi V, Tamburino C. Novel oral anticoagulants versus warfarin in nonvalvular atrial fibrillation: a meta-analysis of 50,578 patients. Int J Cardiol. 2013;167:1237–41. A meta-analysis of three phase III trials comparing NOACs with warfarin.

    Article  PubMed  Google Scholar 

  23. Pisters R, Nieuwlaat R, Lane DA, Crijns HJ, Lip GY. Potential net clinical benefit of population-wide implementation of apixaban and dabigatran among European patients with atrial fibrillation. A modelling analysis from the Euro Heart Survey. Thromb Haemost. 2013;109:328–36. A modelling analysis confirms a profound annual mathematical net clinical benefit of dabigatran and apixaban.

    Article  CAS  PubMed  Google Scholar 

  24. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383:955–62. This meta-analysis firstly includes data for all four NOACs studied in the pivotal phase III clinical trials to assess the relative efficacy and safety of NOACs.

    Article  CAS  PubMed  Google Scholar 

  25. Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L. Randomized Evaluation of Long-Term Anticoagulation Therapy I. Newly identified events in the RE-LY trial. N Engl J Med. 2010;363:1875–6.

    Article  CAS  PubMed  Google Scholar 

  26. Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006;114:119–25.

    Article  PubMed  Google Scholar 

  27. Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation. 2007;115:2689–96.

    Article  CAS  PubMed  Google Scholar 

  28. Lip GY, Laroche C, Dan GA, et al. 'Real-world' antithrombotic treatment in atrial fibrillation: The EORP-AF pilot survey. Am J Med. 2014 Jun;127(6):519–29.

  29. Fumagalli S, Cardini F, Roberts AT, et al. Psychological effects of treatment with new oral anticoagulants in elderly patients with atrial fibrillation: a preliminary report. Aging Clin Exp Res. 2014. doi:10.1007/s40520-014-0243-x.

  30. Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation. 2011;123:2363–72.

    Article  CAS  PubMed  Google Scholar 

  31. Roldan V, Marin F, Fernandez H, et al. Renal impairment in a "real-life" cohort of anticoagulated patients with atrial fibrillation (implications for thromboembolism and bleeding). Am J Cardiol. 2013;111:1159–64.

    Article  PubMed  Google Scholar 

  32. Olesen JB, Lip GY, Kamper AL, et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med. 2012;367:625–35.

    Article  CAS  PubMed  Google Scholar 

  33. Guo Y, Wang H, Zhao X, et al. Sequential changes in renal function and the risk of stroke and death in patients with atrial fibrillation. Int J Cardiol. 2013;168:4678–84. This paper indicates the relationship between worsening renal function and the risk of stroke and death in AF.

    Article  PubMed  Google Scholar 

  34. Limdi NA, Limdi MA, Cavallari L, et al. Warfarin dosing in patients with impaired kidney function. Am J Kidney Dis. 2010;56:823–31.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  35. Sardar P, Chatterjee S, Herzog E, Nairooz R, Mukherjee D, Halperin JL. Novel oral anticoagulants in patients with renal insufficiency: a meta-analysis of randomized trials. Can J Cardiol. 2014;30:888–97. This meta-analysis demonstrates that recommended doses of NOACs are noninferior and relatively safe compared with conventional anticoagulants in AF patients with renal insufficient.

    Article  PubMed  Google Scholar 

  36. Hohnloser SH, Hijazi Z, Thomas L, et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J. 2012;33:2821–30.

    Article  CAS  PubMed  Google Scholar 

  37. Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation—developed with the special contribution of the European Heart Rhythm Association. Europace. 2012;14:1385–413. An important update to the ESC 2010 AF Guideline providing a synopsis of the anticoagulation aspects of AF.

    Article  PubMed  Google Scholar 

  38. Enomoto Y, Iijima R, Tokue M, et al. Bleeding risk with triple antithrombotic therapy in patients with atrial fibrillation and drug-eluting stents. Cardiovasc Interv Ther. 2014;29:193–9.

    Article  CAS  PubMed  Google Scholar 

  39. Task Force M, Lip GY, Windecker S, et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Eur Heart J 2014. doi:10.1093/eurheartj/ehu298.

  40. Bernard A, Fauchier L, Pellegrin C, et al. Anticoagulation in patients with atrial fibrillation undergoing coronary stent implantation. Thromb Haemost. 2013;110:560–8. This study confirms oral anticoagulants should be systemically used in AF patients undergoing coronary stent implantation.

    Article  CAS  PubMed  Google Scholar 

  41. Desai J, Kolb JM, Weitz JI, Aisenberg J. Gastrointestinal bleeding with the new oral anticoagulants–defining the issues and the management strategies. Thromb Haemost. 2013;110:205–12.

    Article  CAS  PubMed  Google Scholar 

  42. Dewilde WJ, Oirbans T, Verheugt FW, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet. 2013;381:1107–15. This trial demonstrates safety of using clopiogrel without aspirin in AF patient taking oral anticoagulants while receiving percutaneous coronary intervention.

    Article  CAS  PubMed  Google Scholar 

  43. Alexander JH, Lopes RD, Thomas L, et al. Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J. 2014;35:224–32.

    Article  CAS  PubMed  Google Scholar 

  44. Gallego P, Roldan V, Marin F, et al. Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation. Thromb Haemost. 2013;110:1189–98.

    Article  CAS  PubMed  Google Scholar 

  45. De Caterina R, Husted S, Wallentin L, et al. Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis—Task Force on Anticoagulants in Heart Disease. Thromb Haemost. 2013;110:1087–107.

    Article  PubMed  Google Scholar 

  46. Lane DA, Lip GY. Patient's values and preferences for stroke prevention in atrial fibrillation: balancing stroke and bleeding risk with oral anticoagulation. Thromb Haemost. 2014;111:381–3.

    Article  CAS  PubMed  Google Scholar 

  47. Oramasionwu CU, Bailey SC, Duffey KE, et al. The association of health literacy with time in therapeutic range for patients on warfarin therapy. J Health Commun. 2014;19 Suppl 2:19–28.

    Article  PubMed  Google Scholar 

  48. Lahaye S, Regpala S, Lacombe S, et al. Evaluation of patients' attitudes towards stroke prevention and bleeding risk in atrial fibrillation. Thromb Haemost. 2014;111:465–73.

    Article  CAS  PubMed  Google Scholar 

  49. Apostolakis S, Sullivan RM, Olshansky B, Lip GY. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT(2)R(2) score. Chest. 2013;144:1555–63.

    Article  CAS  PubMed  Google Scholar 

  50. Gallego P, Roldan V, Marin F, et al. SAME-TTR score, time in therapeutic range and outcomes in anticoagulated patients with atrial fibrillation. Am J Med. 2014. doi:10.1016/j.amjmed.2014.05.023.

  51. Lip GY, Haguenoer K, Saint-Etienne C, Fauchier L. Relationship of the SAME-TT2R2score to poor quality anticoagulation, stroke, clinically relevant bleeding and mortality in patients with atrial fibrillation. Chest. 2014;146:719–26.

  52. Deitelzweig S, Amin A, Jing Y, et al. Medical cost reductions associated with the usage of novel oral anticoagulants vs warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF, and ARISTOTLE trials. J Med Econ. 2012;15:776–85.

    Article  PubMed  Google Scholar 

  53. Deitelzweig S, Amin A, Jing Y, et al. Medical costs in the US of clinical events associated with oral anticoagulant (OAC) use compared to warfarin among non-valvular atrial fibrillation patients ≥75 and <75 years of age, based on the ARISTOTLE, RE-LY, and ROCKET-AF trials. J Med Econ. 2013;16:1163–8.

    Article  PubMed  Google Scholar 

  54. Harrington AR, Armstrong EP, Nolan Jr PE, Malone DC. Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation. Stroke. 2013;44:1676–81. This paper illustrates that NOACs can be cost-effective alternative to warfarin.

    Article  PubMed  Google Scholar 

  55. Lip GY, Kongnakorn T, Phatak H, et al. Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation. Clin Ther. 2014;36:192–210.

  56. Dorian P, Kongnakorn T, Phatak H, et al. Cost-effectiveness of apixaban vs current standard of care for stroke prevention in patients with atrial fibrillation. Eur Heart J. 2014;35:1897–906.

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Qinmei Xiong declares no conflict of interest. Gregory Y. H. Lip declares the receipt of payments for serving as a consultant for Bayer, Astellas, Merck, AstraZeneca, Sanofi, BMS/Pfizer, Biotronik, Portola, and Boehringer Ingelheim, as well as for serving on the speakers bureau for Bayer, BMS/Pfizer, Boehringer Ingelheim, and Sanofi-Aventis.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. University of Birmingham Centre for Cardiovascular Science, City Hospital, Birmingham, UK

    Qinmei Xiong MD & Gregory Y. H. Lip MD

  2. Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark

    Gregory Y. H. Lip MD

  3. Cardiovascular Department, Second Affiliated Hospital of Nanchang University, Nanchang, China

    Qinmei Xiong MD

Authors
  1. Qinmei Xiong MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gregory Y. H. Lip MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gregory Y. H. Lip MD.

Additional information

This article is part of the Topical Collection on Cerebrovascular Disorders

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Xiong, Q., Lip, G.Y.H. Selection of Warfarin or One of the New Oral Antithrombotic Agents for Long-Term Prevention of Stroke among Persons with Atrial Fibrillation. Curr Treat Options Neurol 17, 8 (2015). https://doi.org/10.1007/s11940-014-0331-4

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11940-014-0331-4

Keywords

Search

Navigation